Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 08, 2015 6:25 PM ET

Health Care Technology

Company Overview of Theranos, Inc.

Company Overview

Theranos, Inc. operates as a consumer healthcare technology company. It specializes in the areas of oncology, pediatrics, and geriatrics. The company designs, develops, and manufactures systems that provide access to health information for the early detection and intervention of diseases; and conducts laboratory tests from blood, urine, fluid, solid, and other samples. It also provides a suite of tools for patients and doctors ranging from Websites to mobile applications. The company was founded in 2003 and is based in Palo Alto, California.

1601 South California Avenue

Palo Alto, CA 94304

United States

Founded in 2003





Key Executives for Theranos, Inc.

Founder, Chairman and Chief Executive Officer
President, Chief Operating Officer and Director
Vice President of Finance & Operations
Chief Creative Officer
General Counsel
Compensation as of Fiscal Year 2015.

Theranos, Inc. Key Developments

Theranos Denies Plans To Go Public

Theranos, Inc. denies IPO and being up for sale. Elizabeth Holmes, Founder of Theranos, said, “We're not going to be bought. If approached, reply would be as we have an incredibly long-term vision and we're flattered by the call, but we're just getting started." Elizabeth Holmes said that she has no plans to go public, and that Theranos can continue to grow as a privately held company.

Theranos and AmeriHealth Caritas Announce National Strategic Partnership to Improve Health Care for the Underserved Population

Theranos Inc. and AmeriHealth Caritas announced a national strategic partnership to improve health outcomes by providing greater access to less invasive, more efficient diagnostic tests to Medicaid members and empowering them to fully engage with their physicians in their health care. The partnership represents the first time a Medicaid managed care organization will make Theranos’ innovative diagnostic tests available directly to underserved populations. The strategic partnership between Theranos and AmeriHealth Caritas signifies a shared commitment to bring groundbreaking health care technology to disadvantaged individuals and underserved communities who typically do not have access to these health care advancements. Working with Theranos, AmeriHealth Caritas members will be able to access more convenient, high quality, and less invasive clinician-directed laboratory testing, from a blood sample taken from a tiny finger stick or a micro-sample taken from traditional methods, eliminating the need for larger needles and numerous vials of blood required for most diagnostic laboratory testing. Results to Theranos’ laboratory tests are available more quickly – often in a matter of hours as opposed to days or weeks.

Theranos and Capital BlueCross Team Up to Provide Innovative, Low Cost, Accessible Lab Testing Services in Central Pennsylvania

Theranos, Inc. and Capital BlueCross announced a long-term partnership to introduce Theranos™ revolutionary technology and laboratory services across the region to Capital BlueCross members. The companies have been working together for the last several years to form a strategic partnership in which Theranos™ low-cost, high quality laboratory services will be introduced to Central Pennsylvania. The companies also intend to showcase the impact of Theranos™ services around lowering the cost of care in areas where costs for medical diagnostic testing are high due to the lack of availability of health care resources. Theranos, which received clearance of its lab technology from the FDA last week, is the first lab to publish all of its pricing, and all of its tests are at least 50% below the Medicare reimbursement rate. Theranos will make available its full menu of tests in Central Pennsylvania "from full fertility panels ($35) to simple cholesterol tests ($2.99). In addition to its pricing, Theranos delivers unparalleled transparency around the quality of its testing. As it develops new testing services, the company has committed to submit all of its laboratory-developed tests to FDA for review and approval, and is the only lab to publish and update test proficiency data and customer satisfaction metrics on its website. Theranos has already performed millions of tests since its launch and continues to provide full service labs and testing throughout Arizona and Palo Alto, California. Capital BlueCross reviewed the accuracy and quality of Theranos' systems, technology, science, processes and overall performance over several years.

Similar Private Companies By Industry

Company Name Region
Clairvia Incorporated United States
ICDLogic LLC United States
Cardinal Information Corporation United States
1COMM Medical, Inc. United States
Cerner Math, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Theranos, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at